| Latest Xtl Biopharmaceuticals Adr News Headlines |
| Date | Time | Source | |
| 04/16/2009 | 7:44AM | PRNUS | XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
REHOVOT, Israel, April 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced that on April 15, 2009, it received notification from The Nasdaq Stock Market ("Nasdaq") that the Nasdaq Listing Qualifications Panel (the "Panel") has determined that the Company's American... More...>> |
| 04/06/2009 | 4:15PM | PRNUS | XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2008
REHOVOT, Israel, April 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL), a company engaged in the acquisition, development and commercialization of therapeutics for the treatment of multiple myeloma and hepatitis C, announced today its financial results for the year ended December 31... More...>> |
| 03/18/2009 | 10:24PM | PRNUS | XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of M
REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that it has entered into an asset purchase agreement with Bio-GAL Ltd, a private company, for the rights to a use patent on Recombinant Erythropoietin ("rHuEPO") for the prolongation of multiple myeloma... More...>> |
| 03/18/2009 | 2:31PM | PRNUS | Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the results of its Extraordinary General Meetings ("EGMs") held earlier today.
All of the resolutions at the EGMs were passed. The current board of directors consists of Mark Allouche, Dafna Cohen, Yaron... More...>> |
| 03/11/2009 | 11:05AM | PRNUS | XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
VALLEY COTTAGE, N.Y., March 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that its Extraordinary General Meetings ("EGMs") were postponed for one week in accordance with its articles of association due to the absence of a quorum. The postponed EGMs will take place at... More...>> |
| 02/11/2009 | 4:05PM | PRNUS | XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
VALLEY COTTAGE, N.Y., Feb. 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that Mr. David Grossman and Mr. Boaz Shweiger have been appointed to XTL's Board of Directors, effective today. In addition, Mr. Grossman will also be assuming the role of Co-Chief Executive Officer... More...>> |
| 02/05/2009 | 6:03PM | PRNUS | Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today provided notification that on February 3, 2009 the Company received a letter from a shareholder who owns more than 5% of the Company's outstanding ordinary shares requesting the convening of an... More...>> |
| 02/05/2009 | 2:40PM | PRNUS | XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today provided notification that on February 3, 2009 the Company received a letter from a shareholder who owns more than 5% of the Company's outstanding ordinary shares requesting the convening of an extraordinary... More...>> |
| 01/28/2009 | 4:12AM | PRNUS | XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL.
The Company... More...>> |
| 01/28/2009 | 4:11AM | PRNUS | XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications... More...>> |
| 12/08/2008 | 4:35PM | PRNUS | XTL Biopharmaceuticals Implements Restructuring Plan
VALLEY COTTAGE, N.Y., Dec. 8 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that it is restructuring its operations following the failure of the Bicifadine Phase 2b clinical trial. The company is terminating the employment of 9 employees, representing 75% of its workforce... More...>> |
| 11/18/2008 | 8:05AM | PRNUS | XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
Study failed to meet its primary endpoint
VALLEY COTTAGE, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare... More...>> |
| 10/10/2008 | 2:00PM | PRNUS | Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
VALLEY COTTAGE, N.Y., Oct. 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the results of its Extraordinary General Meetings ("EGMs") held earlier today.
The outcome of the EGMs was as follows: all of the resolutions passed and Jennifer L. Good and Kenneth J. Zuerblis were... More...>> |
| 10/07/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals Announces Completion of the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
VALLEY COTTAGE, New York, Oct. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) announced today that the last patient randomized into the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain has completed the study. This milestone officially marks... More...>> |
| 10/02/2008 | 11:37AM | PRNUS | XTL Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10, 2008
VALLEY COTTAGE, N.Y., Oct. 2 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that its Extraordinary General Meetings ("EGMs") were postponed until October 10, 2008 in accordance with its articles of association due to the absence of a quorum. The postponed EGMs will take... More...>> |
| 08/27/2008 | 6:23PM | PRNUS | Notification of Extraordinary General Meetings and Further Changes to Board Composition
VALLEY COTTAGE, N.Y., Aug. 27 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced a notice convening two Extraordinary General Meetings (the "Meetings"). The Meetings will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science... More...>> |
| 08/15/2008 | 4:25PM | PRNUS | XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
VALLEY COTTAGE, N.Y., Aug. 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) announced today the receipt of a Staff Deficiency Letter from The Nasdaq Stock Market ("Nasdaq") indicating that the Company fails to comply with the audit committee composition requirements of Nasdaq... More...>> |
| 08/14/2008 | 4:05PM | PRNUS | XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors
VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that Samuel H. Rudman, Esq., has been appointed to XTL's Board of Directors, effective as of August 13, 2008.
Mr. Rudman, 40, is a named partner at a U.S. law firm specializing in complex litigation... More...>> |
| 08/14/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals Announces First Half 2008 Financial Results
VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL), a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatitis C, today announced its financial... More...>> |
| 08/05/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals and Presidio Pharmaceuticals Amend License Agreement for Pre-Clinical Hepatitis C Program XTL to Receive
VALLEY COTTAGE, N.Y., Aug. 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) announced today an amendment to its licensing agreement with Presidio Pharmaceuticals, Inc. for its pre-clinical program in Hepatitis C focused on the NS5A target.
Under the terms of the amended license... More...>> |